Georgia Cannabis Tax — 4% State + Local (No Excise Tax)

Last verified: May 2026

The Tax Structure

Georgia’s medical-cannabis tax structure is unusually patient-friendly:

• 4% state sales tax at retail (the standard Georgia state sales-tax rate).
• Local sales tax (varies by jurisdiction; typically 3–4%, totaling 7–8% combined state + local).
• No separate cannabis excise tax — unlike the 10–37% excise rates imposed in most adult-use states.

The total effective tax burden at retail is therefore in the 7–8% range — substantially lower than most state cannabis programs. The relatively low tax burden is a deliberate accessibility choice given the patient population and the program’s goal of treating low-THC oil as medicine rather than recreational consumer good.

Comparative Tax Burden

Comparison to other state programs:

• Georgia medical: ~7–8% effective at retail.
• Florida medical: ~6–7% (no excise; standard state + local sales tax).
• Mississippi medical: ~12.5% (5% excise on first sale + 7% state sales tax).
• Arkansas medical: ~11.5–15.5% (6.5% state sales + 4% privilege tax stacked at wholesale and retail).
• Oklahoma medical: ~9% (7% state excise + ~2% local).
• Colorado adult-use: ~30%+ at retail (state + local excise + special-purpose taxes).
• Washington adult-use: ~37% (the highest in the country).

Georgia’s low effective tax is one of the few advantages of its narrow regulatory framework — the state has not built up the program-administration costs that justify higher excise rates in adult-use states.

The Implication for SB 220

SB 220 (2026) does not change the tax structure. If signed, the 4% state + local sales-tax framework persists. Patients moving from low-THC oil to higher-potency forms (e.g., vaporization for 21+ patients post-Jan 2027) would pay the same retail tax rate.

Some advocates have raised the question of whether Georgia’s tax framework would survive recreational legalization or significantly broader medical expansion — most adult-use states impose separate excise taxes specifically because the broader user population can support higher tax rates without imposing a meaningful access barrier on the medical-patient subset.

Practical Patient Notes

• Pharmacy retail prices include the 4% state + local sales tax.
• The Georgia Department of Revenue collects the sales tax through standard retail channels.
• Health insurance does not cover medical-cannabis purchases (federal Schedule I status precludes coverage). Patients pay out-of-pocket.
• Compared to Florida medical, Georgia tax burden is roughly comparable; compared to Mississippi, Arkansas, or Tennessee’s hemp-derived market, Georgia is lower.
• For Georgia patients without insurance — including the substantial population of self-employed and gig-economy workers in metro Atlanta — medical-cannabis costs are entirely out-of-pocket. Annual costs vary widely based on dosing; chronic-pain patients commonly spend $500–$2,000+ per year on low-THC oil.

The Hemp Tax Comparison

Georgia’s separately regulated hemp-derived intoxicant market (under HB 213 of 2019 + SB 494 of 2024) is taxed under standard retail sales tax (state + local) without any cannabis-specific excise. This means hemp-derived gummies (under 0.3% total THC) sold at smoke shops, vape stores, and dedicated hemp retailers carry the same tax burden as regulated low-THC oil — ~7–8% combined.

The tax-policy implication is that, for many adult Georgians without a qualifying medical condition, hemp-derived products at smoke shops are tax-equivalent to medical low-THC oil at pharmacies. Combined with the much lower acquisition friction (no DPH card required), hemp products have effectively dominated Georgia’s functional cannabis market.